What Capstan Therapeutics does

Capstan Therapeutics was a clinical-stage biotechnology company founded in 2022 and headquartered in San Diego, California. The company developed an in vivo cell engineering platform built on proprietary targeted lipid nanoparticles (tLNP) that deliver mRNA-based instructions to specific cell types directly within living organisms, enabling genetic reprogramming of T-cells in situ. Its lead product candidate, CPTX2309, was an in vivo CAR-T therapy positioned for autoimmune disorders, with secondary indications covering hematological malignancies and monogenic blood disorders. The platform represented an "inside-out" approach to cell therapy intended to eliminate the ex vivo extraction, manufacturing and reinfusion steps associated with traditional autologous CAR-T regimens.

The business model was built around clinical development and eventual commercialization of in vivo cell therapies, with revenue envisioned through therapeutic product sales following regulatory approval. Capstan built on foundational research from the University of Pennsylvania, particularly work from Dr. Hamideh Parhiz and the Field laboratory, under a licensing arrangement that provided the core tLNP intellectual property. The company was backed by a syndicate of specialist biotech investors that funded a $165 million launch round in September 2022 and an oversubscribed $175 million Series B in March 2024 led by RA Capital Management, with participation from Forbion, Johnson & Johnson Innovation – JJDC, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, and Vida Ventures. Prior to the acquisition, no commercial revenue was generated and no product pricing had been disclosed.

In August 2025, AbbVie acquired Capstan Therapeutics for $2.1 billion, completing a transaction announced in June 2025 and integrating Capstan's tLNP-based in vivo CAR-T platform into AbbVie's immunology pipeline. Post-acquisition, Capstan no longer operates as an independent entity; its website redirects to AbbVie, and distribution, regulatory and commercial scaling have been absorbed into AbbVie's global pharmaceutical and immunology infrastructure (~55,000 employees worldwide). The acquisition represents the principal terminal strategic event for the company and the basis on which its trajectory and platform value should be evaluated.

Name

Capstan Therapeutics

Legal name

Capstan Therapeutics, Inc.

Website

https://capstantx.com

Company type

Private

Founded year

2022

Operating status

Acquired

Headcount range

101–250 employees

Short description

Capstan Therapeutics was a clinical-stage biotechnology company developing in vivo CAR-T therapies using targeted lipid nanoparticles to deliver mRNA to T-cells within patients. Acquired by AbbVie in August 2025 for $2.1 billion, it no longer operates as an independent entity.

Ownership category

akta.pro rank

Product category

In vivo cell therapy and gene editing medicines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• In vivo cell therapy
• MRNA therapeutics
• Lipid nanoparticle delivery
• CAR-T cell engineering
• Gene editing medicines

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Therapeutic Product Sales: As a clinical-stage biotech company, Capstan Therapeutics was focused on developing and commercializing in vivo CAR-T therapies. Revenue would come from product sales following regulatory approval, with initial focus on autoimmune disorders and oncology indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Capstan Therapeutics developed in vivo CAR-T cell therapies using a proprietary targeted lipid nanoparticle (tLNP) platform that delivers mRNA-based genetic instructions directly to T-cells within the patient's body. The lead product candidate, CPTX2309, targeted autoimmune disorders, with the platform also applicable to oncology and monogenic blood disorders, eliminating the need for complex ex vivo cell manufacturing associated with traditional CAR-T therapies.

Product overview

Capstan Therapeutics was a biotechnology company that developed a platform of targeted lipid nanoparticles for in vivo cell engineering. The core technology enables precise delivery of RNA-based instructions directly to cells within the living organism, representing an 'inside-out' approach to cell therapy. The company's lead product candidate was CPTX2309, an in vivo CAR-T therapy targeting autoimmune disorders. The platform was designed to create first-in-class treatments for oncology, autoimmune diseases, and monogenic blood disorders. Capstan Therapeutics was acquired by AbbVie in 2025 for $2.1 billion.

Differentiator

Problem solved

Functional benefit

Products and services

• CPTX2309 In vivo CAR-T product candidate aimed at autoimmune disorders, developed using targeted lipid nanoparticle technology to enable genetic programming of T cells directly within the patient's body without ex vivo manufacturing.
• Targeted Lipid Nanoparticle Platform (tLNP) Proprietary technology platform using targeted lipid nanoparticles to deliver RNA-based instructions directly to cells within the living organism, enabling in vivo cell engineering for therapies including CAR T-cell therapies across oncology, autoimmune diseases, and monogenic blood disorders.

Quantifiable outcome

• Elimination of ex vivo manufacturing complexity required by traditional CAR-T approaches

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• AbbVieflagshipStrategic or Co-development PartnerAbbVie acquired Capstan Therapeutics for $2.1 billion in 2025, integrating Capstan's in vivo CAR-T technology platform into AbbVie's immunology pipeline. The acquisition strengthens AbbVie's position in cell therapy for autoimmune diseases. Deal completed in August 2025.
• University of PennsylvaniacoreStrategic or Co-development PartnerCapstan's technology platform is built on research from the University of Pennsylvania, specifically the work of Dr. Hamideh Parhiz and colleagues in the Field laboratory. The company has a licensing relationship for Penn's targeted lipid nanoparticle technology.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Umoja Biopharma: Umoja is developing in vivo CAR-T cell therapies using its VivoVec platform, the closest direct competitor to Capstan's tLNP-based in vivo cell engineering approach with shared modality and target indications in oncology and autoimmunity.
• Orna Therapeutics: Orna is engineering in vivo cell therapies using lipid nanoparticle delivery of circular RNA payloads, directly comparable to Capstan's in vivo mRNA + tLNP platform for cell programming.
• Intellia Therapeutics: Intellia develops in vivo CRISPR-based gene editing using LNPs to deliver Cas9 to the liver and other tissues, sharing Capstan's in vivo delivery paradigm and applying it to hereditary and autoimmune diseases.
• Allogene Therapeutics: Allogene is developing off-the-shelf allogeneic CAR-T cell therapies for hematologic malignancies and autoimmune diseases, a competing "next-generation" cell therapy approach aimed at the same indications as Capstan's CPTX2309.
• Caribou Biosciences: Caribou is developing allogeneic CAR-T cell therapies (e.g., CB-010) using CRISPR-edited iPSC-derived immune cells for oncology and autoimmune indications, directly competing with Capstan's in vivo CAR-T strategy.
• Fate Therapeutics: Fate is developing iPSC-derived off-the-shelf NK and T-cell immunotherapies for cancer and autoimmune disease, representing another "scalable manufacturing-free" cell therapy approach competing with Capstan's in vivo paradigm.

Emerging players

• Beam Therapeutics: Beam is advancing in vivo base editing with LNP delivery to hematopoietic stem cells and the liver, a closely related in vivo gene-editing modality that overlaps with Capstan's mRNA/LNP delivery focus.
• Verve Therapeutics: Verve develops in vivo lipid nanoparticle-delivered gene editing therapies for cardiovascular disease using base editing, sharing Capstan's LNP-mRNA in vivo delivery chassis and underlying scientific foundation.
• Editas Medicine: Editas is developing in vivo and ex vivo gene-editing medicines using CRISPR, sharing technology adjacency with Capstan's tLNP-mRNA in vivo cell engineering platform.

Broad incumbents

• Bristol-Myers Squibb (Cell Therapy): BMS markets approved ex vivo CAR-T therapies Breyanzi and Abecma, serving as the broad incumbent reference product set whose manufacturing complexity and site-of-care limitations Capstan's in vivo approach aims to disrupt.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/capstantx
• LinkedInlinkedin.com/company/capstan-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Capstan Therapeutics